Related Experiment Video
Updated: May 2, 2026

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker
Published on: December 18, 2014
A further experience of propranolol for severe infantile hemangiomas of the face: an observational study
Antonella Greco1, Angelo Massimiliano D'Erme, Barbara Zamma Gallarati
1Department of Health Sciences, University of Florence, Anna Meyer Children's University Hospital, Florence, Italy.
Insights
Propranolol effectively treats infantile hemangiomas (IHs) in infants, particularly those affecting the face. This study confirms the safety and efficacy of propranolol for IH management in young children.
Area of Science:
- Pediatric Oncology
- Dermatology
- Vascular Anomalies
Background:
- Infantile hemangiomas (IHs) are common benign vascular tumors in infants.
- Endothelial cell hyperproliferation characterizes IHs.
- Complicated IHs, especially facial ones, require effective treatment.
Purpose of the Study:
- To evaluate the efficacy and safety of propranolol in treating infantile hemangiomas involving the facial district.
- To add observational data supporting the use of beta-blockers for IH management.
Main Methods:
- Observational study of 14 pediatric patients (3-12 months old) with complicated facial IHs.
- Treatment administered: propranolol.
- Data collected on treatment outcomes and safety profile.
Main Results:
- Propranolol treatment yielded good to very good results in the majority of patients.
- Positive outcomes observed specifically for IHs located in the facial area.
- The safety profile of propranolol was also noted.
Conclusions:
- Propranolol is an effective treatment for infantile hemangiomas, particularly those on the face.
- The study supports the established efficacy and safety of beta-blockers for IH treatment.
- Further data confirms propranolol's role in managing pediatric vascular anomalies.
Abstract:
Infantile hemangiomas (IHs) are the most common proliferating embrional tumors of infancy, which are constituted by endothelial cell hyperproliferation. The authors want to report their observations of further 14 patients suffering from complicated IHs involving the facial district who were treated with propranolol. 14 patients, with ages between 3 and 12 months, completed a cycle of treatment with propanolol. The observational study aimed at focusing IHs involving the facial district. The treatment with propranolol showed good to very good results in the major part of the treated young patients. The authors want to report their experience and add more data in the confirmation of the use of β-blockers for IH (either in efficacy or in safety profile), focusing on the efficacy of propanolol when IHs involve the face.
Related Concept Videos
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Drug Dosing: Infants and Children
